Brandon Couillard
Stock Analyst at Wells Fargo
(4.36)
# 379
Out of 5,005 analysts
145
Total ratings
60.22%
Success rate
14.94%
Average return
Main Sectors:
Stocks Rated by Brandon Couillard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTRA Natera | Initiates: Equal-Weight | $175 | $167.35 | +4.57% | 1 | Sep 22, 2025 | |
| GH Guardant Health | Initiates: Overweight | $72 | $62.84 | +14.58% | 1 | Sep 22, 2025 | |
| A Agilent Technologies | Maintains: Overweight | $140 → $150 | $141.64 | +5.90% | 24 | Sep 15, 2025 | |
| CDNA CareDx | Maintains: Equal-Weight | $19 → $14 | $15.19 | -7.83% | 3 | Aug 8, 2025 | |
| MLAB Mesa Laboratories | Upgrades: Equal-Weight | $100 → $67 | $73.27 | -8.56% | 3 | Aug 8, 2025 | |
| WAT Waters | Maintains: Equal-Weight | $330 → $315 | $328.39 | -4.08% | 5 | Aug 5, 2025 | |
| BRKR Bruker | Maintains: Overweight | $60 → $50 | $36.98 | +35.21% | 5 | Aug 5, 2025 | |
| AVTR Avantor | Maintains: Overweight | $19 → $16 | $14.29 | +11.97% | 5 | Aug 4, 2025 | |
| BIO Bio-Rad Laboratories | Maintains: Equal-Weight | $245 → $265 | $305.49 | -13.25% | 12 | Aug 1, 2025 | |
| BIO.B Bio-Rad Laboratories | Maintains: Equal-Weight | $245 → $265 | $303.30 | -12.63% | 12 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $180 → $175 | $148.73 | +17.66% | 2 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $78 → $95 | $118.26 | -19.67% | 4 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $570 → $565 | $543.32 | +3.99% | 6 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $210 → $205 | $214.99 | -4.65% | 3 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $59 | $62.95 | -6.27% | 1 | May 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $22 → $6 | $8.06 | -25.56% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,125 → $1,200 | $1,314.04 | -8.68% | 5 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $130 → $102 | $94.05 | +8.45% | 2 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $285 → $260 | $132.17 | +96.72% | 11 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $77 → $80 | $67.03 | +19.35% | 6 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $85 | $56.72 | +49.86% | 16 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $3.09 | +223.62% | 1 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $30 → $23 | $20.85 | +10.31% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $0.88 | +1,372.92% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $3.18 | - | 11 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $11 | $2.54 | +333.07% | 2 | Oct 13, 2017 |
Natera
Sep 22, 2025
Initiates: Equal-Weight
Price Target: $175
Current: $167.35
Upside: +4.57%
Guardant Health
Sep 22, 2025
Initiates: Overweight
Price Target: $72
Current: $62.84
Upside: +14.58%
Agilent Technologies
Sep 15, 2025
Maintains: Overweight
Price Target: $140 → $150
Current: $141.64
Upside: +5.90%
CareDx
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $19 → $14
Current: $15.19
Upside: -7.83%
Mesa Laboratories
Aug 8, 2025
Upgrades: Equal-Weight
Price Target: $100 → $67
Current: $73.27
Upside: -8.56%
Waters
Aug 5, 2025
Maintains: Equal-Weight
Price Target: $330 → $315
Current: $328.39
Upside: -4.08%
Bruker
Aug 5, 2025
Maintains: Overweight
Price Target: $60 → $50
Current: $36.98
Upside: +35.21%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $19 → $16
Current: $14.29
Upside: +11.97%
Bio-Rad Laboratories
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $245 → $265
Current: $305.49
Upside: -13.25%
Bio-Rad Laboratories
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $245 → $265
Current: $303.30
Upside: -12.63%
Jul 30, 2025
Maintains: Overweight
Price Target: $180 → $175
Current: $148.73
Upside: +17.66%
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $78 → $95
Current: $118.26
Upside: -19.67%
Jul 24, 2025
Maintains: Overweight
Price Target: $570 → $565
Current: $543.32
Upside: +3.99%
Jul 23, 2025
Maintains: Equal-Weight
Price Target: $210 → $205
Current: $214.99
Upside: -4.65%
May 30, 2025
Initiates: Overweight
Price Target: $59
Current: $62.95
Upside: -6.27%
May 8, 2025
Downgrades: Equal-Weight
Price Target: $22 → $6
Current: $8.06
Upside: -25.56%
May 5, 2025
Maintains: Equal-Weight
Price Target: $1,125 → $1,200
Current: $1,314.04
Upside: -8.68%
Apr 17, 2025
Maintains: Equal-Weight
Price Target: $130 → $102
Current: $94.05
Upside: +8.45%
Jan 23, 2025
Maintains: Buy
Price Target: $285 → $260
Current: $132.17
Upside: +96.72%
Jan 23, 2025
Maintains: Hold
Price Target: $77 → $80
Current: $67.03
Upside: +19.35%
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $85
Current: $56.72
Upside: +49.86%
Aug 27, 2024
Initiates: Overweight
Price Target: $10
Current: $3.09
Upside: +223.62%
Feb 9, 2024
Downgrades: Hold
Price Target: $30 → $23
Current: $20.85
Upside: +10.31%
Jul 13, 2021
Initiates: Buy
Price Target: $13
Current: $0.88
Upside: +1,372.92%
Nov 2, 2017
Downgrades: Hold
Price Target: n/a
Current: $3.18
Upside: -
Oct 13, 2017
Maintains: Buy
Price Target: $9 → $11
Current: $2.54
Upside: +333.07%